[Metastatic stomach cancer: Clinical trials in Asia and in Occident]

Area of Science:

• Oncology
• Medical Genetics

Background:

• Metastatic gastric cancer (MGC) treatment primarily relies on cytotoxic chemotherapy.
• Molecular targeted agents, such as trastuzumab (anti-HER2) and ramucirumab (anti-VEGFR2), offer new therapeutic avenues.
• Current survival outcomes for MGC generally do not exceed one year.

Purpose of the Study:

• To review current MGC treatment protocols and future perspectives.
• To explore observed survival differences between Asian and Caucasian MGC patients.
• To discuss potential contributing factors to these population-specific survival disparities.

Main Methods:

• Review of clinical studies on MGC treatment.
• Analysis of factors influencing treatment efficacy and survival.
• Comparative analysis of outcomes in Asian versus Caucasian patient cohorts.

Main Results:

• Trastuzumab and ramucirumab demonstrate clinical benefit in specific MGC patient subsets.
• Asian patients exhibit significantly longer survival rates compared to Caucasian patients.
• Population-specific factors, including genetic polymorphisms (e.g., affecting fluorouracil availability), histology, surgical approaches, and healthcare practices (neoadjuvant chemotherapy, screening programs), are implicated but do not fully explain the observed survival gap.

Conclusions:

• While targeted therapies have advanced MGC treatment, significant survival disparities persist between Asian and Caucasian populations.
• Further research is needed to elucidate the complex interplay of genetic, clinical, and environmental factors contributing to these differences.
• Understanding these particularities is crucial for optimizing MGC treatment strategies globally.